What question did this study set out to answer?

This research aims to understand the role of the PAF-PAFR pathway in metabolic dysfunction-associated steatotic liver disease (MASLD) related to obesity.

March 28, 2026Open Access

Platelet‐Activating Factor Pathway in Women With Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity

Puntos clave

This research aims to understand the role of the PAF-PAFR pathway in metabolic dysfunction-associated steatotic liver disease (MASLD) related to obesity.
Examined the upregulation of the PAF-PAFR axis in women with MASLD and obesity.
Analyzed inflammatory and histological features associated with MASLD.
Evaluated the reliability of plasma Lp-PLA2 as a biomarker for MASLD severity.
The PAF-PAFR axis is significantly upregulated in obesity-related MASLD.
There is a strong connection between PAFR and inflammatory histological features.
Plasma Lp-PLA2 is not a reliable noninvasive biomarker for assessing MASLD severity in women with obesity.

Resumen

The PAF-PAFR axis is upregulated in obesity-associated MASLD and is strongly linked to inflammatory and injury-related histological features, supporting PAFR as a potential therapeutic target. Conversely, plasma Lp-PLA2 does not appear to be a reliable noninvasive biomarker of MASLD severity in women with obesity.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Cite This Study

Duran‐Bertran et al. (Thu,) studied this question.

synapsesocial.com/papers/69c771dd8bbfbc51511e1ef3 https://doi.org/https://doi.org/10.1002/oby.70178

Me gusta

Guardar

Ver artículo completo